8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)
Published . Updated .
8-K - Atrium Therapeutics filed an 8-K with the SEC on Nov 2 (a notice of a material company event).
Directly affected
- RNA Atrium Therapeutics+1.0% 17d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Atrium Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+21.6% 30d
Eli Lilly and is a peer of Atrium Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+1.5% 30d
Johnson & Johnson is a peer of Atrium Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+11.4% 30d
AbbVie is a peer of Atrium Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.2% 18d
Merck is a peer of Atrium Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+3.1% 30d
Abbott Laboratories is a peer of Atrium Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| RNA | -3.14% | +1.45% | base | after close | after close | after close | after close |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| LLYNo price data for this ticker | — | — | — | — | — | — | — |
| JNJNo price data for this ticker | — | — | — | — | — | — | — |
| ABBVNo price data for this ticker | — | — | — | — | — | — | — |
| MRKNo price data for this ticker | — | — | — | — | — | — | — |
| ABTNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Filed: 2026-11-02 AccNo: 0001193125-26-442601 Size: 13 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Atrium Therapeutics (RNA)
Across 3 earlier stories, Atrium Therapeutics (RNA) the next day averaged +3.40%. The largest gain was +5.72% and the largest drop was -0.24%, from 3 prices.
| Company | When | Average | Largest gain | Largest drop | Prices |
|---|---|---|---|---|---|
| Atrium Therapeutics (RNA) | the next day | +3.40% | +5.72% | -0.24% | 3 |
| Atrium Therapeutics (RNA) | three days later | -1.98% | +3.24% | -6.74% | 3 |
The price since 2 Nov 2026: Atrium Therapeutics (RNA) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| Atrium Therapeutics (RNA) | three days earlier | +1.45% | final price |
| Atrium Therapeutics (RNA) | five days earlier | -3.14% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 38 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 55 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 49 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 75 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 31 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 45 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Abbott Laboratories (ABT) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)”
Companies tied to this story
- RNA Atrium Therapeutics
For “8-K - Atrium Therapeutics, Inc. (0002093101) (Filer),” Atrium Therapeutics (RNA) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> RNA
How “8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)” reaches Atrium Therapeutics (RNA)
The 2 Nov 2026 story “8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)” names Atrium Therapeutics (RNA) because of this story.
Atrium Therapeutics (RNA) is on the page because SEC 8-K filing -> direct issuer disclosure -> RNA
Dates and price levels for Atrium Therapeutics (RNA)
RNA traded between 7.50 and 8.57 across 17 sessions. The latest close on file is 8.31.
What the saved facts support for Atrium Therapeutics (RNA)
14 out of 100
“8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.